CFH rs3766405: Role in AMD Risk and Anti-VEGF Response
The single-nucleotide polymorphism rs3766405 is an intronic variant located within the complement factor H (CFH) gene on chromosome 1. In ophthalmology research, this variant serves as a key haplotype-tagging marker frequently evaluated for its protective association against wet age-related macular degeneration (AMD). Clinical investigations have also examined whether genotypes at this locus correlate with enhanced therapeutic response to intravitreal anti-VEGF medications.
What each genotype means
| Genotype | What the research suggests | Reading |
|---|---|---|
| CC | Carrying two copies of the major C allele is typically recognized as the reference or common ancestral genotype. In multi-marker CFH haplotype models, homozygous CC status is often part of baseline or standard-risk background configurations for age-related macular degeneration. It is not associated with the protective or enhanced therapeutic advantages sometimes attributed to the minor allele. | Informational |
| CT | Carrying one copy of the minor T allele places an individual in an intermediate genetic category across population studies. In haplotype mapping, this genotype frequently tags average-to-lower relative genetic risk profiles for neovascular AMD compared to homozygous major allele carriers. Some pharmacogenomic investigations suggest intermediate responsiveness to standard anti-VEGF injection regimens. | Favorable |
| TT | Carrying two copies of the minor T allele is the least common configuration in most non-Asian populations. Research literature identifies this genotype as a tag for protective CFH haplotypes associated with lower relative odds of developing wet AMD. In observational cohorts, homozygous TT status has also been studied for potential favorable responses to anti-VEGF therapies. | Favorable |
Genomic Location and Variant Classification
The single-nucleotide polymorphism rs3766405 is an intronic C-to-T transition situated within the CFH (complement factor H) gene on chromosome 1q31.3. Because it resides within an non-coding intron rather than altering an amino acid sequence, it does not directly change the primary structure of the factor H protein. Instead, genomic researchers primarily study rs3766405 as a tag SNP—a representative marker that tracks in tight linkage disequilibrium with broader haplotype blocks across the CFH locus. In high-density genetic maps of macular degeneration, rs3766405 is frequently analyzed in conjunction with neighboring variants like rs412852 to capture ancestral haplotype backgrounds that correlate with eye disease susceptibility.
The Biological Role of Complement Factor H
The CFH gene encodes complement factor H, an essential circulating glycoprotein that functions as a critical negative regulator of the alternative complement pathway. Part of the innate immune system, factor H binds to cell surface markers and promotes the inactivation of C3b, preventing unnecessary complement cascade activation and protecting host tissues from uncontrolled inflammatory destruction. In the retina, dysregulated complement activation can lead to chronic, low-grade inflammatory damage to the retinal pigment epithelium and Bruch's membrane. This continuous inflammatory cascade is recognized as a central pathological driver in both early drusen accumulation and late-stage neovascular (wet) age-related macular degeneration.
Associations with Wet AMD and Anti-VEGF Therapy
Multiple ophthalmologic association studies have scrutinized rs3766405 to understand clinical heterogeneity in age-related macular degeneration. Research evaluating multi-SNP CFH haplotypes has identified configurations tagged by the minor T allele as being statistically associated with a lower susceptibility to wet AMD, displaying a relative protective effect compared to high-risk haplotypes anchored by common variants such as rs1061170. Furthermore, pharmacogenomic studies have explored whether carriers of rs3766405 respond differently to intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatments like ranibizumab and bevacizumab. While some cohorts report favorable anatomical and functional improvements among minor allele carriers, broader systematic analyses and large clinical trials (such as AREDS) emphasize that pharmacogenetic interactions remain modest to mixed, warranting cautious interpretation.
Interpreting Genetic Findings in Clinical Context
Although learning your rs3766405 genotype can offer educational insights into your personal genetic architecture, it is neither a diagnostic test nor a standalone predictor of treatment outcomes. Complex diseases like age-related macular degeneration arise from an intricate interplay of dozens of genetic loci, including ARMS2 and other complement genes, alongside lifestyle factors such as age, smoking status, and nutrition. In real-world ophthalmology practice, anti-VEGF medications and AREDS nutritional supplements are prescribed based on established clinical guidelines and retinal imaging rather than isolated genotypes. Patients should never adjust their treatment schedules or discontinue prescribed eye therapies without consulting their retinal specialist or clinical pharmacist.
How common is this variant?
The minor T allele of rs3766405 exhibits significant geographic variation, reaching its highest minor allele frequency in East Asian populations at approximately 0.35 to 0.45. In contrast, it is observed at substantially lower frequencies across European, African, and South Asian ancestral cohorts.
Frequently asked questions
Does having the rs3766405 T allele guarantee I will not get macular degeneration?
No. While research associates the T allele with a statistically reduced relative risk or protective CFH haplotype, complex traits like macular degeneration are influenced by many genes, age, and environmental exposures such as smoking. A protective variant lowers statistical odds but cannot provide complete immunity.
Can rs3766405 genetic testing dictate which anti-VEGF drug I should take?
No. Major ophthalmological guidelines do not recommend altering anti-VEGF medication selection or dosing based solely on CFH genotypes. Clinical decisions are guided by direct physical examination and optical coherence tomography (OCT) imaging conducted by a specialist.
Where is rs3766405 located in the human genome?
The rs3766405 polymorphism is situated within an intron of the CFH gene on the long arm of chromosome 1 (1q31.3). Because it lies in a non-coding region, it functions predominantly as a tag marker for broader genetic variants rather than directly altering protein structure.
How does CFH influence eye health?
The CFH gene produces complement factor H, an innate immune regulator that keeps the body's complement cascade from attacking healthy tissues. Impairments in factor H function can lead to chronic retinal inflammation, contributing to drusen formation and blood vessel leakage seen in AMD.
Sources & further reading
Educational information only, last refreshed 9/8/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs3766405?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29